Yuri Fedoriw

Yuri Fedoriw

Auto-generated profile, based on publicly available information

Yuri Fedoriw

University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2016 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
NMNathan D. Montgomery
Nathan D. Montgomery
NLN. George Liomba
N. George Liomba
CKCoxcilly Kampani
Coxcilly Kampani
RKRobert Krysiak
Robert Krysiak
CSChristopher C. Stanley
Christopher C. Stanley
YFYuri Fedoriw
Yuri Fedoriw
Objectives: The incidence of lymphoproliferative disorders (LPDs) is increasing in sub-Saharan Africa (SSA) due to population growth, aging, and human immunodeficiency virus (HIV). Despite significant burden, resources for diagnosis and treatment of LPDs are limited, with little infrastructure to deliver modern pathology services. Diagnostic and therapeutic decisions are therefore frequently made without tissue confirmation, leading to high rates of misdiagnosis and inappropriate treatment. Methods: We have established a laboratory in Malawi to support clinical and research efforts at a national teaching hospital. Consensus real-time diagnoses are rendered by local pathologists after weekly clinicopathologic teleconferences involving clinicians and pathologists from the United States and Malawi. Additional ancillary studies are then performed in the United States prior to final diagnosis. Results: We report our first 2 years' experience and demonstrate high concordance between real-time diagnoses in Malawi and final diagnoses in the United States (5% major discordance rate for formalin-fixed, paraffin-embedded samples). In addition, we describe characteristics of pathologically confirmed LPDs in Malawi, highlighting differences by HIV status. Conclusions: Our multidisciplinary approach can be a model for strong pathology services that provide direct, real-time support to clinical care and research in SSA.

1 September 2017 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
CPChristian N Paxton
Christian N Paxton
DODennis P O'Malley
Dennis P O'Malley
ABAndrew M Bellizzi
Andrew M Bellizzi
DADeema Alkapalan
Deema Alkapalan
YFYuri Fedoriw
Yuri Fedoriw
EAErica F Andersen
Erica F Andersen
Juvenile xanthogranuloma is a rare histiocytic proliferation primarily affecting infants and young children, characterized by aberrant infiltration of histiocyte-derived cells in the skin, soft tissues and more rarely, visceral organs. Juvenile xanthogranuloma is generally considered to be a benign disorder; most lesions are solitary cutaneous nodules that resolve spontaneously without treatment. However, cases with extracutaneous involvement, multiple lesions, and/or systemic disease often require aggressive therapy. Though molecular studies have provided evidence of clonality in juvenile xanthogranuloma, in support of a neoplastic process, little is known about the genetic profile of juvenile xanthogranuloma. We used molecular inversion probe array technology to evaluate the genomic characteristics (copy number alterations or copy neutral-loss of heterozygosity) of 21 archived cases of juvenile xanthogranuloma (19 solitary, 1 diffuse cutaneous, 1 systemic). Four cases (19%) showed acquired, clonal alterations. Two lesions from a case of diffuse cutaneous juvenile xanthogranuloma showed distinct profiles: JXG-1a contained trisomy 5 and 17 and JXG-1b contained loss of heterozygosity in 5q. The systemic juvenile xanthogranuloma (JXG-2) showed multiple genomic alterations. Only two of 19 solitary juvenile xanthogranulomas showed abnormal genomic profiles: JXG-3 showed gains on 1q and 11q and JXG-4 showed a 7.2 Mb loss in 3p. No recurrent abnormalities were observed among these cases. The presence of non-recurrent copy number alterations in a subset of samples implies that copy number changes are unlikely driving pathogenesis in juvenile xanthogranuloma, but may be acquired during disease progression. The presence of genomic abnormalities in more advanced cases (ie, systemic and diffuse cutaneous juvenile xanthogranuloma) supports this notion, particularly as the advanced cases of juvenile xanthogranuloma presented more genomic complexity.

1 March 2018 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
NMNathan D. Montgomery
Nathan D. Montgomery
TTTamiwe Tomoka
Tamiwe Tomoka
RKRobert Krysiak
Robert Krysiak
EPEric Powers
Eric Powers
MMMaurice Mulenga
Maurice Mulenga
YFYuri Fedoriw
Yuri Fedoriw

1 March 2018 in Clinics In Laboratory Medicine
Verified
Journal Article
Open access
TTTamiwe Tomoka
Tamiwe Tomoka
NMNathan D. Montgomery
Nathan D. Montgomery
EPEric Powers
Eric Powers
BDBal Mukunda Dhungel
Bal Mukunda Dhungel
EMElizabeth A. Morgan
Elizabeth A. Morgan
YFYuri Fedoriw
Yuri Fedoriw
The care of patients with lymphoma relies heavily on accurate tissue diagnosis and classification. In sub-Saharan Africa, where lymphoma burden is increasing because of population growth, aging, and continued epidemic levels of human immunodeficiency virus infection, diagnostic pathology services are limited. This article summarizes lymphoma epidemiology, current diagnostic capacity, and obstacles and opportunities for improving practice in the region.

29 November 2019 in Pathology
Verified
Journal Article
Closed access
PDF file
CRCara Randall
Cara Randall
YFYuri Fedoriw
Yuri Fedoriw

22 February 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
MPMatthew Painschab
Matthew Painschab
KWKate D. Westmoreland
Kate D. Westmoreland
EKEdwards Kasonkanji
Edwards Kasonkanji
TZTakondwa Zuze
Takondwa Zuze
BKBongani Kaimila
Bongani Kaimila
SGSatish Gopal
Satish Gopal
Burkitt lymphoma (BL) is common in sub-Saharan Africa (SSA). In high-income countries, BL is highly curable with chemotherapy. However, there are few prospective studies from SSA describing nonpediatric BL and no regional standard of care. Thirty-five participants age 15 years or older with newly diagnosed BL were enrolled in Malawi from 2013 to 2018. Chemotherapy was administered according to institutional guidelines, with concurrent antiretroviral therapy if HIV infected. Median age was 21 years (range, 15-61) and 15 participants (43%) were HIV infected. Twenty-seven participants (77%) had stage III to IV disease, and 19 (54%) had Eastern Cooperative Oncology Group performance status >1. Among HIV-infected participants, median CD4 count was 130 (range, 29-605) and 10 (67%) had suppressed HIV viral load. Four participants (11%) died before receiving chemotherapy. First-line chemotherapy consisted of: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (n = 22 [71%]); infusional etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (n = 4 [13%]); high-dose methotrexate-based chemotherapy (n = 4 [13%]); and rituximab plus CHOP (n = 1 [3%]). Among 28 evaluable participants, 14 (50%) achieved a complete response. Median overall survival (OS) was 7 months; 1-year OS was 40% (95% confidence interval [CI], 24%-56%). Sixteen (73%) of 22 deaths were a result of disease progression. Compared with CHOP, more intensive chemotherapy was associated with decreased mortality (hazard ratio, 0.24; 95% CI, 0.05-1.02; P = .05). This is among the best characterized prospective cohorts of nonpediatric BL in SSA. Most deaths resulted from progressive BL. Patients who received more intensive therapy seemed to have better outcomes. Defining optimal approaches is an urgent priority in SSA.